Cargando…

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice

Detalles Bibliográficos
Autores principales:	Zhang, Rong, Li, Dedong, Xu, Kun, Yang, Chenxi, Luo, Tingrong, Zhao, Xin, Gao, George F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700333/ https://www.ncbi.nlm.nih.gov/pubmed/34977828 http://dx.doi.org/10.1016/S2666-5247(21)00331-1

Ejemplares similares

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
por: Souza, William M, et al.
Publicado: (2021)

Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020)

SARS-CoV2 vaccine boosters for India
por: Kang, Gagandeep
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralisation de Sars-CoV-2 Delta après vaccination hétérologue
por: Manus, Jean-Marie
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine
por: Wilder-Smith, Annelies, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
por: Cucunawangsih, Cucunawangsih, et al.
Publicado: (2021)

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
por: Atmar, Robert L., et al.
Publicado: (2021)

SARS-CoV-2 vaccine boosters: The time to act is now
por: Petersen, Maya, et al.
Publicado: (2021)

The societal value of SARS-CoV-2 booster vaccination in Indonesia
por: Johnson, Rob, et al.
Publicado: (2023)

Development of an inactivated vaccine candidate for SARS-CoV-2
por: Gao, Qiang, et al.
Publicado: (2020)

Development of an Inactivated Vaccine against SARS CoV-2
por: Pavel, Shaikh Terkis Islam, et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccine for people with HIV
por: Wolday, Dawit, et al.
Publicado: (2022)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
por: Jara, Alejandro, et al.
Publicado: (2021)

Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains
por: Xiao, Chanchan, et al.
Publicado: (2022)

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
por: Tung, Tao-Hsin, et al.
Publicado: (2022)

Neutralisation of SARS‐CoV‐2 by anatomical embalming solutions
por: Quondamatteo, Fabio, et al.
Publicado: (2021)

Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern
por: McMillan, Christopher L.D., et al.
Publicado: (2022)

SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations
por: McGrath, Jonathan, et al.
Publicado: (2023)

Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine
por: Xu, Xingli, et al.
Publicado: (2022)

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
por: Méndez, Constanza, et al.
Publicado: (2023)

Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts
por: Liu, Di, et al.
Publicado: (2023)

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases
por: Liu, Yongmei, et al.
Publicado: (2023)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Vitamin D deficiency and inactivated SARS-CoV-2 vaccines
por: Wu, Chia-Chao, et al.
Publicado: (2021)

VITT with inactivated SARS-CoV-2 vaccine – index case
por: Devi, Kanta, et al.
Publicado: (2022)

An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
por: Khoshnood, Saeed, et al.
Publicado: (2022)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
por: Singanallur, Nagendrakumar B., et al.
Publicado: (2022)

Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
por: Lavezzo, Enrico, et al.
Publicado: (2022)

Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
por: Sundaram, Appavu K., et al.
Publicado: (2021)

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
por: Naranbhai, Vivek, et al.
Publicado: (2022)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
por: Kim, Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mvfc3djm0c7aqj2erk4q32da9j